- Conditions
- Hypophosphatasia (HPP)
- Interventions
- asfotase alfa
- Biological
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Up to 36 Months
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Wilmington, Delaware • Springfield, Missouri + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- cilengitide, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Watertown, Massachusetts
- Conditions
- Autism
- Interventions
- Atomoxetine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 5 Years to 15 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Lexington, Massachusetts
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Squamous Cell Carcinoma of the Esophagus, Stage IIIB Esophageal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer
- Interventions
- cyclodextrin-based polymer-camptothecin CRLX101, Laboratory biomarker analysis, Pharmacological studies
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Stage III Colorectal Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Clobetasol Propionate, Pharmacological Study, Quality-of-Life Assessment, Regorafenib
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 18 more
- Conditions
- Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
- Interventions
- SexHealth II, Contraceptive
- Behavioral · Drug
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 14 Years to 21 Years · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- BMS-214662, laboratory biomarker analysis, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Neoplasm
- Interventions
- Cixutumumab, Laboratory Biomarker Analysis, Pharmacological Study, Temsirolimus
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Houston, Texas
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Madison, Wisconsin
- Conditions
- Pain, Intractable, Breakthrough Pain, Chronic Pain
- Interventions
- Bupivacaine, Opioid
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 31 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- DE-117 Low Dose ophthalmic solution, DE-117 Low/Middle Dose ophthalmic solution, DE-117 Middle Dose ophthalmic solution, DE-117 Middle/High Dose ophthalmic solution, DE-117 High Dose ophthalmic solution, latanoprost ophthalmic solution 0.005%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 14
- States / cities
- Chandler, Arizona • Artesia, California • Glendale, California + 11 more
- Conditions
- Hypertension
- Interventions
- Virtual Hypertension Clinic
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost 0.01% ophthalmic solution, Bimatoprost 0.015% formulation 1 ophthalmic solution, Bimatoprost 0.015% formulation 2 ophthalmic solution, Bimatoprost 0.02% ophthalmic solution, Bimatoprost 0.03% ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Wenatchee, Washington
- Conditions
- Parkinson's Disease
- Interventions
- HNC364
- Drug
- Lead sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Secaucus, New Jersey
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- EF5, therapeutic conventional surgery, biopsy, pharmacological study
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Polycystic Ovary Syndrome, Obstructive Sleep Apnea
- Interventions
- continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
- Device · Drug · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat, Pharmacokinetic Study, Pharmacological Study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 2
- States / cities
- Duarte, California • Buffalo, New York
- Conditions
- Major Depressive Disorder
- Interventions
- Antidepressant + SPD489 (lisdexamfetamine dimesylate), Antidepressant + placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 246 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 15
- States / cities
- Newport Beach, California • San Diego, California • Bradenton, Florida + 12 more
- Conditions
- Amyloid-beta
- Interventions
- Sodium Oxybate, Sleep deprivation
- Drug · Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Asthma
- Interventions
- Lifestyle Factors, Customized use of Dietary Supplements, Currently Accepted Asthma Care Guidelines
- Behavioral · Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Coronary Artery Disease
- Interventions
- Coronary MR Angiography (CMRA)
- Other
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- oblimersen sodium, cytarabine, daunorubicin hydrochloride, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Interventions
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma
- Interventions
- Brentuximab Vedotin, Ceritinib, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 12 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington